Rural-Urban Disparities in Colorectal Cancer Screening, Diagnosis, Treatment, and Survivorship Care: A Systematic Review and Meta-Analysis [0.03%]
城乡在结直肠癌筛查、诊断、治疗和生存护理方面的差异：系统评价与荟萃分析
Aryana Sepassi,Meng Li,Jason A Zell et al.
Aryana Sepassi et al.
Background: Rural residents have a higher prevalence of colorectal cancer (CRC) mortality compared to urban individuals. Policies have been aimed at improving access to CRC screening to reduce these outcomes. However, lit...
Meta-Analysis
The oncologist. 2024 Apr 4;29(4):e431-e446. DOI:10.1093/oncolo/oyad347 2024
Utility of Low-Dose Duvelisib for Advanced Mycosis Fungoides: A Single-Institution Study [0.03%]
低剂量杜韦利西布对晚期真菌样霉病的疗效：单中心研究
Christopher Bazewicz,Nicolena Verardi,Oleg Akilov
Christopher Bazewicz
Duvelisib, a small-molecule phosphatidylinositol 3-kinase-δ,γ inhibitor, has shown efficacy for mycosis fungoides (MF) at dosage ranges of 25-100 mg twice daily (BID), but with significant toxicity. We conducted a retrospective cohort stu...
Ribociclib-Induced Cutaneous Adverse Events in Metastatic HR+/HER2- Breast Cancer: Incidence, Multidisciplinary Management, and Prognostic Implication [0.03%]
转移性HR+/HER2-乳腺癌中 Ribociclib 引起的皮肤不良事件：发生率、多学科管理及预后影响
Riccardo Giovanni Borroni,Michela Bartolini,Mariangela Gaudio et al.
Riccardo Giovanni Borroni et al.
Background: Ribociclib is approved for hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC) treatment, in combination with endocrine therapy. Hematologica...
Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer [0.03%]
在非小细胞肺癌患者联合化免疫治疗后使用Ramucirumab联合多西他赛的前瞻性观察研究
Yuki Katayama,Tadaaki Yamada,Ryo Sawada et al.
Yuki Katayama et al.
Background: A history of pre-administration of immune checkpoint inhibitors has been reported to be associated with good outcomes of ramucirumab (RAM) plus docetaxel (DOC) combination therapy for advanced non-small-cell l...
Observational Study
The oncologist. 2024 May 3;29(5):e681-e689. DOI:10.1093/oncolo/oyae001 2024
Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy [0.03%]
接受免疫检查点抑制剂治疗的患者结核病复燃风险增加
Hsing-Wu Chen,Yao-Wen Kuo,Chung-Yu Chen et al.
Hsing-Wu Chen et al.
Objective: Reports of tuberculosis (TB) during anticancer treatment with immune checkpoint inhibitors (ICIs) are increasing. However, it is not clear whether the use of ICIs is a significant risk factor for TB, including ...
Multicenter Study
The oncologist. 2024 Apr 4;29(4):e498-e506. DOI:10.1093/oncolo/oyad340 2024
Neoadjuvant Intra-arterial Cytoreductive Chemotherapy Improves Outcomes in Lacrimal Gland Adenoid Cystic Carcinoma [0.03%]
新辅助动脉化疗改善泪腺腺样囊性癌的预后
Philippos Apolinario Costa,David T Tse,Pasquale Benedetto
Philippos Apolinario Costa
Background: Lacrimal gland adenoid cystic carcinoma (LGACC) has historically been associated with a poor prognosis even with localized disease, with a survival of 56% at 5 years. In 1988, we treated the first patient with...
A Systematic Review of Clinical Applications of Anti-CD20 Radioimmunotherapy for Lymphoma [0.03%]
抗CD20放射免疫治疗在淋巴瘤临床应用的系统回顾
Michael Durando,Ajay K Gopal,Joseph Tuscano et al.
Michael Durando et al.
Purpose: The clinical efficacy of anti-CD20 radioimmunotherapy (RIT) is due to a combination of extracellular mechanisms involving immune-mediated cytotoxicity, and intracellular mechanisms related to inhibition of CD20 s...
Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung Cancer [0.03%]
在晚期非小细胞肺癌中混合反应的发生率、相关因素及预后意义
David E Gerber,Yating Wang,Suresh S Ramalingam et al.
David E Gerber et al.
Background: Mixed response (MR), a scenario featuring discordant tumor changes, has been reported primarily with targeted therapies or immunotherapy. We determined the incidence and prognostic significance of MR in advanc...
A Feasibility Study Investigating an Exercise Program in Metastatic Cancer Based on the Patient-Preferred Delivery Mode [0.03%]
基于患者偏好的传递方式探讨运动程序在转移性癌症中的可行性研究
Alice Avancini,Anita Borsati,Elisabetta Baldo et al.
Alice Avancini et al.
Background: Feasibility of exercise in patients with metastatic cancer is still a challenge. This study aimed to determine the feasibility and preliminary efficacy of an exercise intervention based on a patient-preferred ...
Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study [0.03%]
兰瑞肽自治胶与替莫唑胺联合治疗进展性胰腺和肠神经内分泌肿瘤：II期SONNET研究
Marianne Pavel,Harald Lahner,Dieter Hörsch et al.
Marianne Pavel et al.
Background: In advanced neuroendocrine tumors (NET), antiproliferative treatment options beyond somatostatin analogs remain limited. Temozolomide (TMZ) has shown efficacy in NET alone or combined with other drugs. ...
Clinical Trial
The oncologist. 2024 May 3;29(5):e643-e654. DOI:10.1093/oncolo/oyad325 2024